Application of Remazolam toluene sulfonate in nerve interventional operation

Effect of Remazolam Sulfonate combined with Alfentanil in patients with neurosurgical interventional surgery

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100048786

Enrollment

Unknown

Registered

2021-07-16

Start date

2021-08-01

Completion date

Unknown

Last updated

2022-03-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

intracranial aneurysm

Interventions

Control Group:Propofol induction

observation group:Remazolam induction

Eligibility

Sex/Gender

All

Age

20 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Subjects who plan to undergo intracranial aneurysm embolization or intracranial aneurysm flow diversion therapy under laryngeal mask ventilation; 2. Age 20-60 years old, gender is not limited; 3. Body mass index (BMI) 1828kg/m2; 4. The American Society of Anesthesiologists (ASA) grades are grades I, II, and III; 5. The estimated operation time does not exceed 90 minutes; 6. Voluntarily participated and signed the informed consent; 7. Liver and kidney function is normal.

Exclusion criteria

Exclusion criteria: 1. Those with a history of severe heart, brain, lung, liver, kidney and metabolic diseases; 2. Those who have a history of abnormal surgical anesthesia recovery in the past; 3. ECG prompt: heart rate 180mmHg and (or) diastolic blood pressure >110mmHg in patients with preoperative hypertension, or III; 13. Patients with large aneurysms who need to block blood flow; 14. Alcoholics.

Design outcomes

Primary

Measure	Time frame
blood pressure;heart rate;Bispectral index;	—

Countries

China

Contacts

Public ContactLi Xiujie

The First Affiliated Hospital of Zhengzhou University

276600193@qq.com+86 15738314993

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026